Richard Burwick
Cedars-Sinai Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Richard Burwick as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:27 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04725812 · Complement Regulation to Undo Systemic Harm in PreeclampsiaCedars-Sinai Medical Center · terminated · Preeclampsia, Severe Preeclampsia, Eculizumab · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:27 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:27 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- Urinary excretion of C5b-9 is associated with the anti-angiogenic state in severe preeclampsia.Am J Reprod Immunol · 201529 citationsRCR 1.2
- Complement blockade with eculizumab for treatment of severe Coronavirus Disease 2019 in pregnancy: A case series.Am J Reprod Immunol · 202212 citationsRCR 1.0
- Blinded comparison of cervical portio length measurements by digital examination vs Cervilenz.Am J Obstet Gynecol · 20099 citationsRCR 0.4
- Does the use of fetal fibronectin in an algorithm for preterm labor reduce triage evaluation times?J Matern Fetal Neonatal Med · 20138 citationsRCR 0.4